Compare Pfizer with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GSK PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GSK PHARMA PFIZER/
GSK PHARMA
 
P/E (TTM) x 39.0 32.4 120.3% View Chart
P/BV x 6.6 12.9 51.0% View Chart
Dividend Yield % 0.5 1.2 42.3%  

Financials

 PFIZER   GSK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
GSK PHARMA
Mar-19
PFIZER/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8403,595 106.8%   
Low Rs2,0801,253 166.0%   
Sales per share (Unadj.) Rs455.0184.7 246.4%  
Earnings per share (Unadj.) Rs93.826.3 356.7%  
Cash flow per share (Unadj.) Rs109.429.2 375.1%  
Dividends per share (Unadj.) Rs22.5020.00 112.5%  
Dividend yield (eoy) %0.80.8 92.1%  
Book value per share (Unadj.) Rs658.2126.3 521.1%  
Shares outstanding (eoy) m45.75169.40 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.513.1 49.6%   
Avg P/E ratio x31.692.2 34.2%  
P/CF ratio (eoy) x27.183.1 32.6%  
Price / Book Value ratio x4.519.2 23.4%  
Dividend payout %24.076.1 31.5%   
Avg Mkt Cap Rs m135,420410,626 33.0%   
No. of employees `0002.65.0 53.0%   
Total wages/salary Rs m3,2385,372 60.3%   
Avg. sales/employee Rs Th7,911.46,306.7 125.4%   
Avg. wages/employee Rs Th1,230.91,083.1 113.6%   
Avg. net profit/employee Rs Th1,630.7898.0 181.6%   
INCOME DATA
Net Sales Rs m20,81531,281 66.5%  
Other income Rs m1,6741,023 163.6%   
Total revenues Rs m22,48932,304 69.6%   
Gross profit Rs m5,7126,009 95.1%  
Depreciation Rs m714486 146.9%   
Interest Rs m736 1,215.0%   
Profit before tax Rs m6,5996,540 100.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m2,3092,373 97.3%   
Profit after tax Rs m4,2914,454 96.3%  
Gross profit margin %27.419.2 142.9%  
Effective tax rate %35.036.3 96.4%   
Net profit margin %20.614.2 144.8%  
BALANCE SHEET DATA
Current assets Rs m27,16720,061 135.4%   
Current liabilities Rs m8,91714,543 61.3%   
Net working cap to sales %87.717.6 497.0%  
Current ratio x3.01.4 220.9%  
Inventory Days Days6857 119.4%  
Debtors Days Days3014 214.1%  
Net fixed assets Rs m8,86214,343 61.8%   
Share capital Rs m4581,694 27.0%   
"Free" reserves Rs m29,65619,704 150.5%   
Net worth Rs m30,11321,398 140.7%   
Long term debt Rs m252 1,250.0%   
Total assets Rs m39,40039,113 100.7%  
Interest coverage x91.51,091.0 8.4%   
Debt to equity ratio x00 888.2%  
Sales to assets ratio x0.50.8 66.1%   
Return on assets %11.111.4 97.1%  
Return on equity %14.220.8 68.5%  
Return on capital %22.131.9 69.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m428534 80.2%   
Fx outflow Rs m7867,091 11.1%   
Net fx Rs m-358-6,557 5.5%   
CASH FLOW
From Operations Rs m9783,994 24.5%  
From Investments Rs m351-1,433 -24.5%  
From Financial Activity Rs m-1,099-3,584 30.7%  
Net Cashflow Rs m231-1,023 -22.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 50.7 126.0%  
Indian inst/Mut Fund % 7.5 10.2 73.5%  
FIIs % 4.9 23.8 20.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 15.4 153.9%  
Shareholders   85,207 102,036 83.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Dec 6, 2019 | Updated on Dec 6, 2019

DIVIS LABORATORIES share price has hit an all time high at Rs 1,824 (up 1.0%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.0%) and PFIZER (up 1.0%). The top losers include AJANTA PHARMA and BLISS GVS PHARMA .

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Dec 6, 2019 03:31 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS